The UOS token experienced a sharp 20.24% drop within a 15-minute span, falling from $0.00266985 to $0.00213, close to its 24-hour low of $0.00208155. Over longer periods, the token also declined, down 19.12% over one hour and 13.10% over 24 hours. Trading volume over 24 hours was $64,668. No specific reason was identified for this sudden price drop, highlighting market volatility for this digital asset.
The UOS token's recent sharp drop is contextualized by Pluang's broader cryptocurrency market data. As of Oct 24, 2026 02:31 WIB, 36 of 50 major cryptocurrencies on Pluang rose while 13 fell. Notable movers include Fantom (FTM) down 2.05% at Rp11.382 with a typical hold time of 88 days, Filecoin (FIL) up 2.00% at Rp17.629 with 42% sell and 58% buy order activity, and PancakeSwap (CAKE) up 1.77% at Rp39.034 with 19% sell and 81% buy order activity and a typical hold time of 75 days.
The CHMP of the European Medicines Agency has recommended approval for Johnson & Johnson's TALVEY (talquetamab) combined with daratumumab, with or without pomalidomide, for treating adults with relapsed or refractory multiple myeloma who have had at ...
The European Medicines Agency's CHMP has recommended approving Johnson & Johnson's TALVEY® (talquetamab) combined with daratumumab for treating relapsed or refractory multiple myeloma earlier in the treatment process, starting from the second line. T...
The European Medicines Agency's CHMP has recommended approval for Johnson & Johnson's TALVEY® (talquetamab) in combination with daratumumab for treating relapsed or refractory multiple myeloma (RRMM) in patients who have had at least one prior therap...
Fortrea Holdings and Omico have formed a partnership to enhance precision oncology research in Australia by linking cancer patients to biomarker-matched clinical trials. This collaboration combines Fortrea's oncology trial expertise with Omico's Prec...
Fortrea Holdings and Omico have formed a partnership to accelerate precision oncology research in Australia by combining Fortrea's clinical trial expertise with Omico's Precision Oncology Screening Platform (PrOSPeCT). This collaboration aims to impr...
